日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / China-US

New medicine for prostate cancer available in China

chinadaily.com.cn | Updated: 2019-11-28 16:49
Share
Share - WeChat

New medicine to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC) is available in China to save those at high risk of developing metastases.

The Xian Janssen Pharmaceutical Ltd announced on Wednesday that ERLEADA (apalutamide) was put on the market in China after being granted by the China National Medical Products Administration (NMPA) in September, recognizing the urgent unmet need for patients with nmCRPC who currently have few treatment options.

ERLEADA is an androgen receptor inhibitor that works by preventing androgen from binding to the androgen receptor. It has been shown to delay the time to distant metastasis. Treatment with ERLEADA has also shown to result in the control of Prostate-Specific Antigen (PSA) levels, which is an important indicator during the early treatment and prognosis of patients with prostate cancer.

According to Professor Zhou Liqun, Head of Urology Department in Peking University First Hospital, the five year survival rate for advanced mCRPC patients is only 3% before the new method of endocrine treatment. "This rate increased to only 30% even with new treatment. So it is urgent to postpone progression and to maintain quality of life for patients living with nmCRPC and the approval of ERLEADA presents a new treatment option that can potentially addres this treatment.

The incidence rate of prostate cancer in China has increased and become one of the top five of the most common male cancers in the country over the past decade. The androgen-deprivation therapy (ADT) is the current standard of care for nmCRPC. However, if after initial sustained treatment with ADT, the cancer cells continue to progress without distant metastasis, patients will enter a stage called nmCRPC. Without interventions, 90% of patients with nmCRPC will eventually develop bone metastases, which can lead to pain, fractures and spinal cord compression.

According to data from a clinical study, ERLEADA reduced the risk of advanced metastasis or death by 72% and increased median metastasis-free survival by over two years among patients with nmCRPC who are undergoing continuous ADT treatment.

Professor Wang Jianye, Dean of Beijing Hospital and Director of National Center of Gerontology, said "In recent years, urology and oncology doctors are working on new NM-CRPC treatment and medicine. ERLEADA optimizes the standard NM-CRPC treatment in China and provides quality time for patients and their families."

"As one of the leading pharmaceutical companies in China, Xian Janssen has been dedicated to helping patients with prostate cancer in China. We recognize the varied needs of patients across all stages of prostate cancer, which require collaborative efforts from government, society and the healthcare industry to address. To help patients with prostate cancer receive better treatment, we are committed to exploring the full potential of our solutions in addressing unmet treatment needs across all stages of disease progression," said Asgar Rangoonwala, President of Xian Janssen.

ERLEADA is now available in major Chinese cities including Beijing, Shanghai, Guangzhou and Tianjin. Xian Janssen is supporting the China Primary Healthcare Foundation to launch a Patient Access Program that helps low-income patients in China access treatment with ERLEADA.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 亚洲国产精品久久久久秋霞蜜臀 | 91香蕉视频导航 | 国产中文字幕一区 | 亚洲操片 | 久久久久伊人 | 欧美亚洲国产精品第一页 | 国产一区二区精品尤物 | 美女色站 | 亚洲美女亚洲精品久久久久 | 一级毛片真人免费观看 | 国产成人精品视频 | 妈妈的朋友酷客影响 | 魔法骑士在线观看免费完整版高清 | 黄a在线观看 | 91天堂| 久久久www成人免费精品 | 欧美电影网站在线观看影片 | 狠狠伊人 | 九九热精品视频在线播放 | 欧美日韩亚洲国产 | 亚洲国产系列久久精品99人人 | 国产福利视频 | 成人免费激情视频 | 天天摸夜夜摸夜夜狠狠摸 | 欧美精品免费线视频观看视频 | 91高清在线成人免费观看 | 夜夜夜精品视频 | 在线观看国产 | 岛国色情A片无码视频免费看 | 久久久婷婷一区二区三区不卡 | 成人性爱视频在线观看 | 亚洲一区二区三区免费视频 | 久久中文字幕在线 | a毛片在线看免费观看 | 亚洲午夜久久久精品影院 | 99热在线国产 | jizzjizz日本护士视频 | 欧美成人一区二区三区在线视频 | 丝袜美腿中文字幕 | 久久91综合国产91久久精品 | 天天噜噜揉揉狠狠夜夜 |